


Claims

1. A compound of formula I



(I)

or a pharmaceutically acceptable salt thereof;

wherein R1 is H, methyl or ethyl; R2 is H or phenyl and


B is

1). $-(CH_2)_3NHC(NH)NH_2$,

2). $-(CH_2)_3NH_2$,

3). $-(CH_2)_2NH_2$ or


4)




wherein asterisk (*) indicates the point of attachment;

with the proviso that when B is $-(CH_2)_3NHC(NH)NH_2$, then R1 is not hydrogen.

2. A compound of claim 1 whereby the compound has the structure




3. A compound of claim 1 whereby the compound has the structure




5

4. A compound of claim 1 whereby the compound has the structure




5. A compound of claim 1 whereby the compound has the structure




10


6. A compound of claim 1 whereby the compound has the structure




7. A compound of claim 1 whereby the compound has the structure



8. A compound of claim 1 whereby the compound has the structure



9. A compound of claim 1 whereby the compound has the structure



10. A pharmaceutical composition comprising of a compound according to any of claims 1 to 9 as an active ingredient together with a pharmaceutically acceptable diluent, carrier and/or excipient.

11. The use of a compound of any of claims 1 to 9, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for treating a disease or condition in mammals where interaction with the somatostatin receptor subtype 4 optionally together with the subtype 1 is indicated to be useful.